|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 比伐卢定对行经皮冠状动脉介入的急性冠状动脉综合征患者的作用:ACUITY试验的一项亚组分析 | Stone G.W. White H.D. Ohman E.M. 杜媛 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，0，8： | 6 |
| 2 | 急性ST段抬高的心肌梗死患者行经皮冠状动脉介入时对远端微循环的保护:一项随机对照试验 | Stone G.W. Webb J. Cox D.A. 赵和平 | 2005 | 世界核心医学期刊文摘(心脏病学分册)2005，0，7： | 3 |
| 3 | 急性ST段抬高心肌梗死患者经皮冠状动脉介入治疗时远端微循环保护的随机对照试验 | Stone G.W. Webb J. Cox D.A. 黄卫东 | 2005 | 世界核心医学期刊文摘(神经病学分册)2005，0，7： | 2 |
| 4 | 治疗延迟对急性心肌梗死直接经皮冠状动脉介入治疗预后的影响:来自CADILLAC试验的分析 | Brodie B.R. Stone G.W. Cox D.A. 尹涛 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，0，11： | 2 |
| 5 | 西罗莫司和紫杉醇洗脱冠状动脉支架的有效性和安全性 | Stone G.W. Moses J.W. Ellis S.G. 黄浙勇 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，0，8： | 2 |
| 6 | 常规早期开始与延迟选择性应用糖蛋白IIb/IIIa抑制剂治疗急性冠状动脉综合征的比较:ACUITY时限试验 | Stone G.W. Bertrand M.E. Moses J.W. 刘少伟 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，0，8： | 1 |
| 7 | Modeling hurricane waves and storm surge using integrally-coupled, scalable computations显示文摘 | J.C. Dietrich M. Zijlema J.J. Westerink L.H. Holthuijsen C. Dawson R.A. Luettich R.E. Jensen J.M. Smith G.S. Stelling G.W. Stone | 2010 | Coastal Engineering2010，，1： | 1 |
| 8 | Impact of Baseline Haemorrhagic risk on the Benefit of Bivalirudin Versus Unfractionated Heparin in Patients Treated with Coronary Angioplasty: A meta-regression analysis of randomized trials显示文摘 | G. Tarantini S.J. Brener A. Barioli A. Gratta G. Parodi R. Rossini E.P. Navarese G. Niccoli A.C. Frigo G. Musumeci S. Iliceto G.W. Stone | 2013 | American Heart Journal2013，，： | 1 |
| 9 | ST段抬高型与非ST段抬高型急性心肌梗死患者行直接经皮冠状动脉介入术后早期及晚期预后(来自于CADILLAC试验)显示文摘We determined the outcomes of patients with acute ST-segment elevation(STE) myocardial infarction(STEMI) and non-STEMI(NSTEMI) after primary percutaneous coronary intervention(PCI). The prognosis after primary PCI in STEMI has been extensively studied and defined. Outcomes of patients who undergo primary PCI for NSTEMI are less well established. In total, 2,082 patients with ongoing chest pain for >30 minutes consistent with acute MI were randomized to balloon angioplasty versus stenting, each with/without abciximab. Of 1,964 patients, STEMI was present in 1,725(87.8%) and NSTEMI in 239(12.2%). Compared with STEMI, those with NSTEMI were more likely to have delayed time-to-hospital arrival(2.4 vs 1.8 hours, p=0.0002) and increased door-to-balloon time(3.2 vs 1.9 hours, p< 0.0001). Patients with NSTEMI were more likely to have Thrombolysis In Myocardial Infarction grade 3 flow at baseline(37.3%vs 19.4%, p< 0.0001) and higher ejection fraction(58.7%vs 55.8%, p=0.001), but similar rates of postprocedural Thrombolysis In Myocardial Infarction grade 3 flow. At 1 year, patients with NTEMI had similar mortality(3.4%vs 4.4%, p=0.40) but higher rates of major adverse cardiac events(24.0%vs 16.6%, p=0.007) that was driven by more frequent ischemic target vessel revascularization(21.8%vs 11.9%, p< 0.0001). In conclusion, patients with acute MI without STE who are treated with primary PCI have marked delays to treatment, similar late mortality, and increased rates of ischemic target vessel revascularization compared with patients with STEMI, despite more favorable angiographic features at presentation and similar reperfusion success. The adverse prognosis of patients with NSTEMI should be recognized and efforts made to decrease reperfusion times. | Cox D.A. Stone G.W. Grines C.L. 杜媛 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，，12： | 1 |
| 10 | 以血小板糖蛋白IIb/IIIa受体抑制作为隐静脉桥支架置入术的辅助治疗:随机分配接受血管阻塞或滤网血栓保护后的不同疗效显示文摘Aims: Although embolic protection devices reduce complications during saphenous vein graft(SVG) stenting, adverse events still occur in ~10%of patients. IIb/IIIa antagonists have not been proven effective during SVG intervention. We hypothesized that adjunctive use of these agents might enhance the efficacy of embolic protection devices. Methods and results: In the prospective, multicentre FilterWire EX Randomized Evaluation trial, 651 patients undergoing SVG stenting were randomized to either filter-based FilterWire EX or balloon occlusion/aspiration GuardWire embolic protection devices. IIb/IIIa inhibitor use was at the discretion of the investigator, with randomization stratified by intended use. Patients pre-selected for IIb/IIIa inhibitor use(n=345) had higher baseline risk, with increased 30-day major adverse cardiac events(MACE, 13.0 vs. 8.0%, P=0.03). GuardWire assigned patients treated with IIb/IIIa inhibitors had higher 30-day MACE compared with those not treated with IIb/IIIa inhibitors(16.0 vs. 6.3%, P=0.007). In contrast, MACE in high-risk FilterWire patients treated with IIb/IIIa inhibitors were similar to their lower risk, untreated counterparts(9.9 vs. 9.5%, P=0.89). Multivariable analysis detected a borderline significant(P=0.056) interaction for lower MACE between FilterWire and IIb/ IIIa inhibitor use. Adjustment by the propensity to use IIb/IIIa inhibitors resulted in a significant(P=0.023) interaction for lower MACE rates. IIb/IIIa inhibition in conjunction with FilterWire was associated with less abrupt closure, no reflow, or distal embolization. Conclusion: IIb/IIIa antagonists may improve procedural outcome during SVG stenting in high risk patients, utilizing filter-based embolic protection devices. | Jonas M. Stone G.W. Mehran R. C.Rogers 苏畅 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，9： | 0 |
| 11 | 因急性心肌梗死行直接血管成形术的患者中侧支血流对心肌再灌注和梗死面积的影响显示文摘背景:在接受直接经皮冠状动脉介入(PCI)的患者中,基线时梗死相关动脉(IRA)的侧支血流的预后意义仍存在争论。作者旨在观察在因急性心肌梗死(AMI)行直接PCI的患者中基线IRA侧支血流对再灌注成功率、 | Sorajja P. Gersh B.J. Mehran R. G.W. Stone 赵君 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，，11： | 0 |
| 12 | 老年急性心肌梗死患者首次行冠状动脉介入治疗的预后:降低晚期血管成形术并发症的阿昔单抗和设备的调查试验(CADILLAC) | Guagliumi G. Stone G.W. Cox D.A. 梁磊 | 2005 | 世界核心医学期刊文摘(心脏病学分册)2005，0，3： | 0 |
| 13 | 紫杉醇药物洗脱支架用于经皮冠状动脉血运重建的成本效益分析:TAXUS-IV临床试验的结果显示文摘Objectives: This study sought to compare aggregate medical care costs for patients undergoing percutaneous coronary intervention with paclitaxel-eluting stents(PES) and bare-metal stents(BMS) and to formally evaluate the incremental cost effectiveness of PES for patients undergoing single-vessel percutaneous coronary intervention. Background: Although the cost effectiveness of SES has been studied in both clinical trials and decision-analytic models, few data exist on the cost effectiveness of alternative drug-eluting stent(DES) designs. In addition, no clinical trials have specifically examined the cost effectiveness of DES among patients managed without mandatory angiographic follow-up. Methods: We performed a prospective economic evaluation among 1,314 patients undergoing percutaneous coronary revascularization randomized to either PES(N=662) or BMS(N=652) in the TAXUS-IV trial. Clinical outcomes, resource use, and costs(from a societal perspective) were assessed prospectively for all patients over a 1-year follow-up period. Cost effectiveness was defined as the incremental cost per target vessel revascularization(TVR) event avoided and was analyzed separately among cohorts assigned to mandatory angiographic follow-up(n=732) or clinical follow-up alone(n=582). Results: The PES reduced TVR by 12.2 events per 100 patients treated, resulting in a 1-year cost difference of $572 per patient with incremental cost-effectiveness ratios of $4,678 per TVR avoided and $47,798/quality-adjusted life year(QALY) gained. Among patients assigned to clinical follow-up alone, the net 1-year cost difference was $97 per patient with cost-effectiveness ratios of $760 per TVR event avoided and $5,105/QALY gained. Conclusions: In the TAXUS-IV trial, treatment with PES led to substantial reductions in the need for repeat revascularization while increasing 1-year costs only modestly. The cost-effectiveness ratio for PES in the study population compares reasonably with that for other treatments that reduce coronary restenosis, including alternative drug-eluting stent platforms. | Bakhai A. Stone G.W. Mahoney E. D.J. Cohen 赵君 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员